{"id":"W4411229260","doi":"10.1016/j.esmoop.2025.105303","title":"Safety overview and management of inavolisib alone and in combination therapies in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer (GO39374)","year":2025,"lang":"en","type":"article","venue":"ESMO Open","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada); Princess Margaret Cancer Centre","funders":"Genentech; Sun Pharma; Natera; Relay Therapeutics; Seagen; MacroGenics; Puma Biotechnology; Loxo Oncology; Ribon Therapeutics; BeiGene; Mersana Therapeutics; Les Laboratories Pierre Fabre; Astellas Pharma; Eisai; Jazz Pharmaceuticals; F. Hoffmann-La Roche; AstraZeneca; Invitae; Daiichi Sankyo Europe; National Cancer Institute; Servier; Gilead Sciences; Sanofi; Memorial Sloan-Kettering Cancer Center; GlaxoSmithKline; Amgen; Pfizer; Celgene; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Breast cancer; Medicine; Oncology; HER2 negative; Internal medicine; Cancer; Metastatic breast cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00214262,0.0003148777,0.0007498622,0.0004855939,0.0002330167,0.0007604561,0.0006610756,0.0005704274,0.002081715],"category_scores_gemma":[0.001102888,0.0001541566,0.000856886,0.0006169637,0.0002862618,0.0004084817,0.0002352015,0.001298408,0.0004462773],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008566252,"about_ca_system_score_gemma":0.0007750032,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004378514,"about_ca_topic_score_gemma":0.001528845,"domain_scores_codex":[0.9992096,0.0003061266,0.00009272464,0.0001040998,0.0002202045,0.0000671721],"domain_scores_gemma":[0.9990724,0.0001881103,0.0005023373,0.00004837781,0.0001077486,0.00008086275],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.03975936,0.002073868,0.02297847,0.003745127,0.001006508,0.0005467211,0.0002924324,0.003225475,0.05314467,0.0007817065,0.008547273,0.8638984],"study_design_scores_gemma":[0.05748955,0.2822699,0.2381888,0.003110379,0.005698688,0.01560807,0.0006030897,0.01045909,0.09264196,0.002984449,0.2907446,0.0002014008],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8557045,0.1117152,0.004420827,0.003099008,0.000156332,0.0009114196,0.003039572,0.0005345569,0.02041861],"genre_scores_gemma":[0.9677059,0.02114739,0.00293233,0.001455191,0.0002526546,0.0004329877,0.003686733,0.00005786122,0.002328917],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00214262,"threshold_uncertainty_score":0.01133144,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01318522498311948,"score_gpt":0.3310736711880635,"score_spread":0.3178884462049441,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}